Stock Track | TransMedics Group Soars 7.69% After Hours on Stellar Q2 Earnings, Raised Guidance

Stock Track

Jul 31, 2025

Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, significantly outperformed analyst expectations, driving investor enthusiasm.

TransMedics reported quarterly earnings of $0.92 per share, dramatically surpassing the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year growth and beating the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.

Adding to the positive sentiment, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's President and CEO, Waleed Hassanein, expressed confidence in their strategy, emphasizing their focus on achieving 10,000 US NOP (National OCS Program) transplants by 2028. The strong financial performance, coupled with recent developments such as receiving conditional IDE approval for the Next-Gen OCS™ Lung trial and the launch of the OCS NOP digital ecosystem, underscores TransMedics' growth trajectory and market position in the advanced medical equipment and technology sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1140057061"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140057061\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140057061?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 04:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140057061","market":"us","top_or_hot":-1,"title":"Stock Track | TransMedics Group Soars 7.69% After Hours on Stellar Q2 Earnings, Raised Guidance","media":"Stock Track","content":"<p>Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, significantly outperformed analyst expectations, driving investor enthusiasm.</p>\n\n<p>TransMedics reported quarterly earnings of $0.92 per share, dramatically surpassing the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year growth and beating the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.</p>\n\n<p>Adding to the positive sentiment, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's President and CEO, Waleed Hassanein, expressed confidence in their strategy, emphasizing their focus on achieving 10,000 US NOP (National OCS Program) transplants by 2028. The strong financial performance, coupled with recent developments such as receiving conditional IDE approval for the Next-Gen OCS™ Lung trial and the launch of the OCS NOP digital ecosystem, underscores TransMedics' growth trajectory and market position in the advanced medical equipment and technology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Group Soars 7.69% After Hours on Stellar Q2 Earnings, Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Group Soars 7.69% After Hours on Stellar Q2 Earnings, Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-31 04:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, significantly outperformed analyst expectations, driving investor enthusiasm.</p>\n\n<p>TransMedics reported quarterly earnings of $0.92 per share, dramatically surpassing the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year growth and beating the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.</p>\n\n<p>Adding to the positive sentiment, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's President and CEO, Waleed Hassanein, expressed confidence in their strategy, emphasizing their focus on achieving 10,000 US NOP (National OCS Program) transplants by 2028. The strong financial performance, coupled with recent developments such as receiving conditional IDE approval for the Next-Gen OCS™ Lung trial and the launch of the OCS NOP digital ecosystem, underscores TransMedics' growth trajectory and market position in the advanced medical equipment and technology sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1140057061","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140057061","pubTimestamp":1753907644,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"股票追踪|TransMedics Group盘后飙升7.69%，第二季度盈利出色，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, significantly outperformed analyst expectations, driving investor enthusiasm.\nTransMedics reported quarterly earnings of $0.92 per share, dramatically surpassing the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year growth and beating the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.\nAdding to the positive sentiment, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's President and CEO, Waleed Hassanein, expressed confidence in their strategy, emphasizing their focus on achieving 10,000 US NOP (National OCS Program) transplants by 2028. The strong financial performance, coupled with recent developments such as receiving conditional IDE approval for the Next-Gen OCS™ Lung trial and the launch of the OCS NOP digital ecosystem, underscores TransMedics' growth trajectory and market position in the advanced medical equipment and technology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}